Literature DB >> 23139229

Increased risk of arthropathies and joint replacement surgery in patients with genetic hemochromatosis: a study of 3,531 patients and their 11,794 first-degree relatives.

Maria Elmberg1, Rolf Hultcrantz, Julia F Simard, Åke Carlsson, Johan Askling.   

Abstract

OBJECTIVE: Genetic hemochromatosis (GH) is an autosomal recessive disease in individuals of Northern and Western European descent. Heterozygosity for the C282Y mutation is common (6-20%). Arthropathy is one of the few complications of GH suggested not to be associated with iron body stores; synovial iron deposition remains in iron-depleted patients. Previous studies suggest an elevated prevalence of clinical and radiographic signs of arthropathy in patients with GH, and 2 smaller studies suggest a possibly elevated risk of joint replacement surgery, but more mixed results are shown regarding risks with HFE genotype. We therefore assessed the risks of arthropathy and joint replacement surgery in patients with GH and in their first-degree relatives (FDRs).
METHODS: We performed a population-based cohort study of 3,531 patients with GH and of their 11,794 FDRs (assumed to be heterozygous for the C282Y mutation) using nationwide Swedish population-based health and census registers. Hazard ratios (HRs) of arthropathies and joint replacement surgeries among patients and their FDRs (versus the general population) were assessed using Cox regression.
RESULTS: Between 1997 and 2005, 406 of 3,531 patients were reported/hospitalized with any noninfectious arthropathies, including osteoarthritis, corresponding to an HR of 2.38 (95% confidence interval [95% CI] 2.14-2.64). Patients were also at increased risk of hip replacement (HR 2.77, 95% CI 2.27-3.38) and knee replacement (HR 2.14, 95% CI 1.58-2.88) surgery. Among the 11,794 FDRs (patients excluded), we found no increased risk of any of the joint morbidities.
CONCLUSION: Patients with GH, but not their FDRs, are at increased risk of arthropathies, including the need for joint replacement surgery.
Copyright © 2013 by the American College of Rheumatology.

Entities:  

Mesh:

Year:  2013        PMID: 23139229     DOI: 10.1002/acr.21883

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  10 in total

Review 1.  [Hemochromatosis].

Authors:  B Oppl; J Zwerina
Journal:  Z Rheumatol       Date:  2015-09       Impact factor: 1.372

Review 2.  HFE-related hemochromatosis: an update for the rheumatologist.

Authors:  Emma Husar-Memmer; Andreas Stadlmayr; Christian Datz; Jochen Zwerina
Journal:  Curr Rheumatol Rep       Date:  2014-01       Impact factor: 4.592

3.  Effect of C282Y genotype on self-reported musculoskeletal complications in hereditary hemochromatosis.

Authors:  António Camacho; Thomas Funck-Brentano; Márcio Simão; Leonor Cancela; Sébastien Ottaviani; Martine Cohen-Solal; Pascal Richette
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240

4.  Age-dependent ferritin elevations and HFE C282Y mutation as risk factors for symptomatic knee osteoarthritis in males: a longitudinal cohort study.

Authors:  Lauren Kennish; Mukundan Attur; Cheongeun Oh; Svetlana Krasnokutsky; Jonathan Samuels; Jeffrey D Greenberg; Xi Huang; Steven B Abramson
Journal:  BMC Musculoskelet Disord       Date:  2014-01-08       Impact factor: 2.362

5.  Bone and joint complications in patients with hereditary hemochromatosis: a cross-sectional study of 93 patients.

Authors:  Chi-Duc Nguyen; Vincent Morel; Adeline Pierache; Georges Lion; Bernard Cortet; René-Marc Flipo; Valérie Canva-Delcambre; Julien Paccou
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-07-16       Impact factor: 5.346

6.  HFE hemochromatosis screening in patients with severe hip osteoarthritis: A prospective cross-sectional study.

Authors:  Bastian Oppl; Emma Husar-Memmer; Svea Pfefferkorn; Martha Blank; Peter Zenz; Eva Gollob; Christian Wurnig; Alfred Engel; Andreas Stadlmayr; Gökhan Uyanik; Wolfgang Brozek; Klaus Klaushofer; Jochen Zwerina; Christian Datz
Journal:  PLoS One       Date:  2018-11-14       Impact factor: 3.240

7.  Common conditions associated with hereditary haemochromatosis genetic variants: cohort study in UK Biobank.

Authors:  Luke C Pilling; Jone Tamosauskaite; Garan Jones; Andrew R Wood; Lindsay Jones; Chai-Ling Kuo; George A Kuchel; Luigi Ferrucci; David Melzer
Journal:  BMJ       Date:  2019-01-16

8.  Screening for hereditary haemochromatosis in patients undergoing knee arthroplasty : a retrospective cohort study of 2,035 patients.

Authors:  Elisha Krasin; Aviram Gold; Samuel Morgan; Yaniv Warschawski
Journal:  Bone Jt Open       Date:  2021-12

Review 9.  Treatment of nongout joint deposition diseases: an update.

Authors:  Tristan Pascart; Pascal Richette; René-Marc Flipo
Journal:  Arthritis       Date:  2014-05-08

10.  EMQN best practice guidelines for the molecular genetic diagnosis of hereditary hemochromatosis (HH).

Authors:  Graça Porto; Pierre Brissot; Dorine W Swinkels; Heinz Zoller; Outi Kamarainen; Simon Patton; Isabel Alonso; Michael Morris; Steve Keeney
Journal:  Eur J Hum Genet       Date:  2015-07-08       Impact factor: 4.246

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.